BRD2 Upregulation as a Pan-Cancer Adaptive Resistance Mechanism to BET Inhibition
Bromodomain and extraterminal motif (BET) inhibitors, such as JQ1, are promising cancer therapeutics that target epigenetic regulators, particularly BRD4. However, resistance to BET inhibitors (BETi)...
biorxiv.org